Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
| 10.96 Delayed Data As of Mar 31 |  -0.025 / -0.23%Today’s Change | 4.07 Today|||52-Week Range 13.42 | +153.59% Year-to-Date |
Latest AUPH News | Press Releases
| Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains? Mar 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 10.98 |
| Today’s open | 11.12 |
| Day’s range | 10.89 - 11.30 |
| Volume | 86,435 |
| Average volume (3 months) | 2,983,464 |
| Market cap | $1.6B |
Data as of 4:00pm ET, 03/31/2023
Growth & Valuation
| Earnings growth (last year) | +45.50% |
| Earnings growth (this year) | +2.07% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +193.89% |
| P/E ratio | NM |
| Price/Sales | 4.57 |
| Price/Book | 3.84 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TLRYTilray Brands Inc | +0.02 | +0.79% |
| BCRXBioCryst Pharmaceuti... | -0.04 | -0.48% |
| MORFMorphic Holding Inc | +0.37 | +0.99% |
| TVTXTravere Therapeutics... | +0.39 | +1.77% |
Data as of 4:00pm ET, 03/31/2023
Financials
| Next reporting date | May 10, 2023 |
| EPS forecast (this quarter) | -$0.22 |
| Annual revenue (last year) | $134.0M |
| Annual profit (last year) | -$108.2M |
| Net profit margin | -80.71% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
